1 option
Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling / Matthew J. Higgins, Xin Yan, Chirantan Chatterjee.
- Format:
- Book
- Author/Creator:
- Higgins, Matthew J.
- Series:
- Working Paper Series (National Bureau of Economic Research) no. w24957.
- NBER working paper series no. w24957
- Language:
- English
- Physical Description:
- 1 online resource: illustrations (black and white);
- Place of Publication:
- Cambridge, Mass. National Bureau of Economic Research 2018.
- Summary:
- We provide causal evidence that regulation induced product shocks significantly impact aggregate demand and firm performance in pharmaceutical markets. Event study results suggest an average loss between $569 million and $882 million. Affected products lose, on average, $186 million over their remaining effective patent life. This leaves a loss of between $383 million and $696 million attributable to declines in future innovation. Our findings complement research that shows drugs receiving expedited review are more likely to suffer from regulation induced product shocks. Thus, it appears we may be trading off quicker access to drugs today for less innovation tomorrow. Results remain robust to variation across types of relabeling, market sizes, and levels of competition.
- Notes:
- Print version record
- August 2018.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.